Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company, through its subsidiaries, is engaged in the discovery and development of its Anticalin class of bio therapeutics for patients. Its drug candidates include PRS-080, PRS-060, PRS-110 and 300-Series. The Company’s platform technology focuses on low molecular-weight Anticalin proteins that bind tightly and specifically to a range of targets. Its PRS-080 is an Anticalin drug candidate targeting hepcidin, a peptide mediator that is a regulator of iron absorption and storage. Its PRS-060 targets IL-4 receptor alpha-chain (IL-4RA), a cell surface receptor expressed on immune cells in the lung epithelium and mucosal layer. Its PRS-110 is a protein-based antagonist of cMet that blocks both ligand-dependent and ligand-independent activity. Its 300-Series is a platform within a product for immuno-oncology. Its 300-Series Anticalin proteins target checkpoint proteins.
